Objectives: Voriconazole is approved for management of invasive fungal diseases (IFDs) in paediatric patients. We analysed plasma trough concentrations and explored their association with endpoints of antifungal therapy.
Introduction
Voriconazole is a synthetic second-generation antifungal triazole with broad-spectrum antifungal in vitro activity against the majority of clinically important yeasts and moulds, including Candida spp., Cryptococcus neoformans, Aspergillus and other hyaline moulds, dematiaceous moulds as well as dimorphic moulds. 1 Phase II and III clinical trials in adults have demonstrated safety and efficacy in the treatment of superficial and invasive candidiasis, invasive aspergillosis, scedosporiosis and fusariosis, and the compound is approved for these indications in subjects ≥12 years in both the USA and the European Union. The recommended intravenous adult dosage is 4 mg/kg twice daily (day 1: 6 mg/kg twice daily), and the oral dosage is 200 mg twice daily (day 1: 400 mg twice daily) (,40 kg body weight: 100 mg twice daily with a loading dose of 200 mg twice daily on day 1). 2, 3 Whereas the disposition of voriconazole in adolescents ≥12 years and weighing .50 kg is similar to that in adults, 4 an initial dose-finding study demonstrated that paediatric patients 2 -11 years of age have a higher capacity for elimination per kg of body weight, resulting in lower, potentially non-therapeutic, exposures at similar dosages. 5 A population pharmacokinetic analysis based on the initial and a subsequently conducted intra-individual dose escalation study suggested that an intravenous dosage of 7 mg/kg twice daily and an oral dosage of 200 mg twice daily (oral suspension) without loading dosages in children 2-11 years of age was comparable to exposure levels observed in adult patients receiving the approved dosing regimen. 6 Based on these pharmacokinetic trials, 5, 6 compassionate use data in children with life-threatening invasive fungal diseases (IFDs) 7 and the perceived medical need, the compound was approved in the European Union in children 2-11 years of age. 2 The pharmacokinetics of voriconazole are complex and involve hepatic metabolization through several CYP450 isoenzymes as well as polymorphisms in its major metabolic pathway, resulting in non-linear pharmacokinetics and unpredictable dose -exposure relationships that are further influenced by drug -drug interactions and variable oral bioavailability, particularly in children. 4, 8 While emerging clinical data generated largely in adults suggest a potentially important role for therapeutic drug monitoring (TDM), 9 -13 little is known about the dose-concentration -effect relationship of voriconazole and the compound's safety and efficacy in paediatric patients. In order to obtain more data on exposure, safety, efficacy and dose-exposure-effect relationships of voriconazole, we analysed steady-state plasma trough concentrations and explored their association with endpoints of antifungal therapy.
Patients and methods

Study design
The study was a single-centre retrospective non-comparative cohort study of immunocompromised paediatric patients who were considered to require therapy with voriconazole between October 2002 and January 2010. Patients eligible for inclusion were ≤18 years of age, had received at least 1 day of treatment with voriconazole and had at least one plasma trough concentration obtained under conditions of steady state. Voriconazole was administered at recommended dosages 2 until occurrence of intolerance or maximum efficacy for treatment of presumed or documented IFDs, as empirical therapy or as primary or secondary antifungal prophylaxis. All patients received several concurrent therapies for management of their underlying diseases and their complications. Ethics Committee approval was not required as this was a non-interventional study with TDM being part of standard medical care. Written informed consent for antifungal therapy as part of the medically indicated measures of supportive care and for data collection was obtained within the consent procedure for cancer treatment, haematopoietic stem cell transplantation (HSCT) and specialized medical care. Data collection was accomplished by a pseudonymized standardized case report form.
Measurement of voriconazole plasma levels
For the purpose of this analysis, only plasma samples obtained under conditions of steady state at 12 h post-dosing at trough were accepted. Steady state was considered to be reached at 12 h following intravenous or oral administration of the full loading dose or, in cases without loading dose and administration of the maintenance dose, on day 6 of twice daily dosing. 2 Blood samples were obtained in heparinized vials, promptly centrifuged and concentrations of voriconazole in plasma were determined by a validated HPLC method. 14 The lower limit of quantification (LOQ) was 0.2 mg/L; for statistical analysis, concentrations below LOQ were counted as 0.0 mg/L. Accuracies and intra-and inter-day variability (precision) of the assay were within +10%.
Assessment of safety and tolerance
Independent of cause, laboratory parameters of hepatic and renal organ function were measured at baseline (BL), at the time of TDM and at the end of treatment (EOT). In addition, the most pathological value during treatment was evaluated for each parameter and episode. Clinical and laboratory adverse events (AEs) were recorded and graded according to current Common Terminology Criteria of Adverse Events (CTCAE) set forth by the US National Cancer Institute 15 in consideration of age-related reference values. A clinical AE attributable to voriconazole was defined as an event that was not present at BL but developed during the treatment and resolved completely after cessation of therapy.
Assessment of antifungal efficacy
Coding of IFDs and outcome was performed by the investigators responsible for data analysis (S. P. and A. H. G.) according to the 2008 EORTC/MSG criteria. 16, 17 A favourable response ('success') in patients with possible/probable/proven infections included either 'complete response' or 'partial response', and failure included 'stable disease' or progression or death due to the infection. For prophylaxis and empirical therapy, success was defined as completion of therapy without recurrent or breakthrough fungal infection, no discontinuation due to AEs and survival at the time of discontinuation of the compound. 18 For the purpose of correlating plasma concentrations with efficacy, the absence of recurrent or breakthrough infection during voriconazole prophylaxis/empirical therapy was graded as a favourable response ('success').
Statistical considerations
For statistical analyses, Predictive Analysis Software (PASW) version 18.0.0 was used. Comparisons of laboratory values during therapy were performed using the Wilcoxon signed rank test. Relationships between clinical or laboratory data and trough concentrations were analysed by non-parametric Spearman correlation, the Mann-Whitney U-test or by Kruskal-Wallis ANOVA. A two-sided P value ≤0.05 was considered statistically significant.
Results
Patients
During the observation period of the study, a total of 252 separate courses of treatment with voriconazole were administered to 107 children and adolescents. Of these, 74 had a total of 101 courses with at least one voriconazole trough concentration obtained under conditions of steady state and constitute the study population.
Patients' demographic and clinical characteristics are summarized in Table 1 . Forty-two of the 74 patients were male and 32 were female. Most were of Caucasian origin (93%) and the mean age at the initiation of antifungal therapy was 10.2 years (range 0.2-18). The overwhelming majority of patients had haematological malignancies (66.2%) or bone marrow failure syndromes (14.9%) as underlying conditions. Almost half of the patients (45%) had a post-allogeneic HSCT status and in 66% of the 101 treatment courses patients had been at least temporarily granulocytopenic.
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Indications and administration of voriconazole
Treatment indications and details of treatment with voriconazole are outlined in Table 2 . Patients received voriconazole mostly for primary or secondary prophylaxis [47 and 32 of 101 courses, respectively (78%)]. Voriconazole was administered as empirical therapy in 2 courses, as treatment for possible invasive fungal infection in 7 courses and as treatment for probable or proven IFDs in 13 courses. Voriconazole was combined with other systemic antifungal agents in 6 of 20 courses for therapy of fungal infections.
The median duration of treatment with voriconazole was 40 days (range 6 -1002). The majority of patients (81%) received voriconazole orally; in 15% treatment was started intravenously and switched to oral, and in 4% of the courses voriconazole was given by the intravenous route. The median maintenance dose was 195.9 mg twice daily (range 35 -500), corresponding to 4.8 mg/kg of body weight twice daily (range 2.2 -17.4; wide dose range explained by the fixed oral dose for children ,12 years during the time of the study). Dosage modifications occurred in 31 courses because voriconazole trough concentrations were considered too low (11) or too high (2) . Other reasons for dosage modifications were change of the application form (9), intolerance (3) or unknown (6) .
TDM of voriconazole
Out of a total of 362 TDM measurements for voriconazole, 251 were obtained at trough under conditions of steady state (mean+SD number of samples per patient: 3.4+4.3). The median time interval between drug administration and plasma sampling was 12 h (range 12 -13). Initial and subsequent trough concentrations were measured at a median of 32 days (range 1 -790) and 68 days (range 1 -790), respectively, after starting therapy. Trough plasma concentrations ranged from ,0.2 to 14.9 mg/L (mean+SD: 1.59+2.17) without differences of the mean trough concentration between the different paediatric age groups. In 22%, 42% and 58% of samples, voriconazole concentrations were ,0.2, ≤0.5 and ≤1.0 mg/L, respectively (Table 3) ; there was a high intra-and inter-individual variability of trough concentrations as depicted in Figure 1 . 
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No significant relationships between daily dose (in mg/kg) and trough concentrations were observed, either for the entire cohort or for the intravenous or orally administered doses. There was, however, a weak correlation between orally administered absolute doses (in mg/day) and the attained voriconazole concentrations (r¼0.207 and P¼0.002; Spearman correlation). In addition, there was no significant correlation between dose and trough concentrations for children aged 2-6 or 7-12 years; for children ≤24 months and adolescents .12 years, there was a weak relationship between dose and voriconazole trough concentration (r¼0.461 and P¼0.009, and r¼0.254 and P¼0.004, respectively).
Safety and tolerance
Independent of causal relationships, AEs were observed in 77 of 101 courses. Increases in hepatic transaminases (59%), serum bilirubin (28%) and alkaline phosphatase (20%) while on treatment were frequent and mostly of grade I or II (Table 4) . Increases in hepatic function parameters during therapy were frequent. However, whereas mean aspartate aminotransferase (AST) and alkaline phosphatase values were slightly elevated at EOT (P,0.01, Wilcoxon signed rank test), mean serum bilirubin and alanine aminotransferase (ALT) values were not different from BL (Figure 2 ). While we observed weak correlations between dose (in mg/kg) and ALT, AST and alkaline phosphatase values (range 0.172-0.327, P,0.05, Spearman correlation), there were no consistent relationships between voriconazole trough concentrations and these simultaneously determined laboratory parameters. Of note, the proposed threshold value of 5.5 mg/L was not found to be discriminative for increases in hepatic function parameters. Considering the CTCAE grading, we found a relationship between the maximum trough concentration per episode and ≥CTCAE grade I AST (P ¼ 0.012, MannWhitney U-test), but not ≥CTCAE grade III AST elevations. No relationship between maximum, median or mean voriconazole concentrations and other laboratory or clinical AEs graded according to CTCAE were observed.
Responses to treatment
Responses to treatment with voriconazole are listed in Table 5 Pieper et al.
for treatment failure included possible pulmonary mould breakthrough infection in six cases and AEs that were at least possibly related to voriconazole treatment in eight cases. Among the 13 courses with probable and proven IFDs, complete or partial responses were observed in three courses and stable disease in six courses. Four patients failed therapy with voriconazole (death due to invasive pulmonary aspergillosis in one case and progressive disease in three cases). Among the seven courses administered for possible IFDs, three had a complete response and two had a partial response; stable disease was observed in one course, and in one course treatment failed (progressive lung infiltrates). Altogether 75 of 101 treatment courses (74.2%) were considered as treatment success and 26 were considered treatment failures. Overall survival at EOT and at 3 months after the EOT was 97% and 91%, respectively; only one patient died due to IFD. In this mixed population with a large proportion of patients receiving voriconazole for a prophylactic indication, we found no correlations between maximum dose/episode and initial, median and mean trough concentrations and treatment response, respectively.
Discussion
The results of this retrospective analysis attest to the safety and clinical usefulness of voriconazole in severely immunocompromised children and adolescents. TDM revealed high inter-and intra-individual variability in trough plasma concentrations, with a quarter of samples being below the lower LOQ of 0.2 mg/L. There were no predictable relationships between dose and trough concentration, and no consistent relationships were observed between voriconazole exposure in plasma at trough and measures of toxicity and efficacy.
Clinical Phase III trials in adult patients with life-threatening IFDs that used fixed standard doses have demonstrated similar 19 to superior 20 clinical efficacy of voriconazole relative to standard treatments. While predictive exposure-effect relationships have been observed in animal models, 21 no clinically relevant correlations between exposure and effect were found during the clinical development of the compound.
2,3 However, following regulatory approval, several cohort studies in adults suggested a potentially important role for TDM to optimize treatment outcomes. 9 -13,22 A consistent finding of these reports is the high inter-and also intra-individual variability in voriconazole trough concentrations, as well as a relevant proportion of samples with undetectable (i.e. ≤0.2 mg/L) voriconazole concentrations. 10, 11, 13, 22 A few studies were able to demonstrate a correlation between higher trough concentrations and hepatic 9, 23, 24 and neurological 22, 23, 25, 26 AEs, and a correlation of higher trough concentrations with antifungal efficacy. 9, 10, 12, 27 The principal utility of TDM was demonstrated by Pascual et al. 22 In this study that included 52 patients with IFDs, lack of response was significantly more frequent in patients with voriconazole concentrations ≤1 mg/L (n ¼6/13) than in those with voriconazole concentrations .1 mg/L (n ¼15/39); adjusting blood concentrations to .1 mg/L was feasible and resulted in complete resolution of infection in all six cases. 22 Finally, in the most comprehensive study to date, concentration -response relationships of voriconazole were analysed in a total of 825 patients from nine previously published clinical trials. 28 While logistic regression analysis showed a non-linear concentration -response relationship with the probability lower at the extremes, Monte Carlo simulation revealed that a trough: MIC ratio of between 2 and Therapeutic drug monitoring of voriconazole 5 was associated with a near-maximal probability of response and that this parameter can be used as an exposure target. The situation in paediatric patients is even more complex, as dose finding is still on-going and fewer data exist on exposureeffect relationships. Whereas the disposition of voriconazole in infants ,2 years has not been formally investigated, pharmacokinetic studies in children 2-11 years of age have demonstrated a faster weight-normalized clearance rate compared with adults with lower exposure at similar dosages. 5 In adolescents 12 to ,18 years, exposure at similar dosages appears to be comparable to adults; however, young adolescents 12 -14 years with low body weight (,50 kg) appear to metabolize voriconazole more similarly to children and may need the higher children's dosages to match the adult exposures. 4 Two different population pharmacokinetic analyses that were based on two different datasets obtained in children 2 -11 years revealed that an intravenous dosage of 7 mg/kg twice daily and an oral dosage of 200 mg twice daily given as oral suspension without loading dosages provided comparable exposures to those observed in adult patients receiving the approved dosing regimen. 6, 29 However, conventional pharmacokinetic analyses of one of the datasets suggested that intravenous doses .7 mg/kg are needed in children to match adult exposures, that the oral bioavailability of voriconazole in children is much lower than that in adults and that higher weight-adjusted oral dosages than those used for intravenous treatment are required. 30 These observations were confirmed by a subsequent pharmacokinetic study 31 and, as a consequence, an intravenous dose of 8 mg/kg twice daily (day 1: 9 mg/kg twice daily) and an oral dose of the suspension of 9 mg/kg twice daily is now recommended in the European Union for children 2 to ,12 years and 12-14 years weighing ,50 kg and is being further investigated in Phase II trials conducted by the manufacturer. 32, 33 In a pharmacokinetic and pharmacodynamic study that included 46 patients who were children and adolescents with possible/probable/proven IFDs, a significant pharmacodynamic association between a voriconazole trough plasma concentration ,1 mg/L and survival was found. 29 In a similar study in 30 paediatric patients, including 19 subjects with proven/probable IFDs, voriconazole plasma concentrations showed a significant relationship with early outcome, but not with late outcome or mortality. 34 Consistent with our data and the paediatric studies discussed above, 4 -6,30,31 these investigators also found a high pharmacokinetic variability, particularly after enteral dosing. Importantly, in our study and those reported thus far, the suggested dosing target of 1 mg/L is not reached by 40% -70% of patients with the current dosing regimen. 29,34 -37 In those studies with consequent dose adjustments, median daily doses of 20 -40 mg/kg have been required to achieve plasma concentrations .1 mg/L. 34, 37 This observation raises fundamental questions as to the paediatric dose finding of voriconazole and, considering the strong dataset of Troke et al., 28 underscores the need for use of TDM of voriconazole in patients with life-threatening IFDs. Of note, the situation in antifungal prophylaxis is different, as there are no data in this setting to allow for an evidence-based assessment.
In a population of severely immunocompromised children, no unexpected toxicities were observed and the rate of treatment discontinuations due to at least possibly related AEs was 9.9%. Parameters of hepatic function did not show consistent trends during voriconazole therapy, and no consistent relationships were found between dose or exposure and AEs. These safety data are similar to other paediatric studies with sufficient data, where the rate of drug discontinuations due to AEs was between 5% and 19%. 7, 30, 37, 38 Similar to our observations, increases in hepatic transaminases were the most commonly observed AEs, followed by skin eruptions, 7, 29, 30, 35, 36, 38 and no correlation between dose or exposure and AEs could be established. 29, 30, 35, 36, 38 Although the assessment of efficacy is limited in our study by its retrospective nature, different comorbidities and different indications for use of voriconazole, reporting outcomes is relevant in the context of patient safety. Considering the IFD-related failure rates of 6.3% and 30.8% in the prophylactic and therapeutic setting, respectively, these outcomes compare favourably with the limited paediatric data reported for allogeneic HSCT patients receiving voriconazole prophylaxis (3/56, 5.3%) 38 and immunocompromised patients with IFDs receiving voriconazole treatment (25/58, 43%). 7 In contrast to the complex analysis of Neely et al. 29 that used patient mortality as an endpoint, and the correlation of voriconazole exposure with early response in the study published by Soler-Palacin et al., 34 we found no consistent correlations between dose or concentrations and treatment response.
In conclusion, voriconazole had acceptable safety and useful efficacy in the management of severely immunocompromised paediatric patients with IFDs or being at risk for IFDs. Assessment of drug exposure without structured intervention revealed high inter-and intra-individual variability, with 20% and .50% of observed voriconazole plasma trough concentrations being ,0.2 and ≤1 mg/L, respectively. Across all age groups, there were no predictable relationships between dose and trough concentration, and no consistent relationships were observed between voriconazole exposure and measures of toxicity and efficacy. Nevertheless, based on a comprehensive pharmacokinetic and pharmacodynamic analysis that also included paediatric patients, 28 we strongly advocate TDM of voriconazole in paediatric patients with life-threatening IFDs with a preliminary dosing target of a voriconazole trough :MIC ratio between 2 and 5.
